Physician profile
Mark J Schefkind
NPI 1972500650
$2,612.33
in general payments reported to CMS, 2019-2025
19 companies · $376 in 2025
The $376 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $153 · 2021: $259 · 2022: $772 · 2023: $547 · 2024: $398 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $767.33 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Alcon Vision LLC | $356.56 | 2019-2025 | Clareon, Eysuvis, Rocklatan |
| Sun Pharmaceutical Industries INC. | $253.43 | 2019-2025 | Cequa |
| Notal Vision, INC. | $218.76 | 2022 | |
| Allergan, INC. | $144.18 | 2020-2022 | |
| Oyster Point Pharma, INC. | $142.33 | 2022-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $137.48 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $118.03 | 2024-2025 | Xdemvy |
| Rayner Intraocular Lenses Limited | $104.36 | 2023-2025 | Omidria, Rayone Spheric, Rayone Emv |
| Bausch & Lomb Americas INC. | $76.12 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Harrow Eye, LLC | $52.20 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.26 | 2019-2021 | |
| Thea Pharma INC. | $39.85 | 2023-2024 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $35.76 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $34.92 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.79 | 2025 | Tepezza |
| Dompe US, INC. | $22.39 | 2022 | |
| Kala Pharmaceuticals, INC. | $20.94 | 2021 | |
| Shire North American Group INC | $14.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schefkind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.